TriPath Investment By Roche Boosts Stock 36% In August, Index Jumps 11%
This article was originally published in The Gray Sheet
Executive Summary
A $40 mil. investment in TriPath Imaging by pharmaceutical and diagnostics giant Roche was the driving force behind a 36.1% jump in TriPath's stock price in August. The issue gained 2-3/16 to close the month at 8-1/4.
You may also be interested in...
Cytyc/Roche Trials Of PCR Tests With ThinPrep Samples To Start In November
Cytyc and Roche Diagnostics plan to commence patient enrollment in November for a four-site clinical trial of Roche Cobas Amplicor polymerase chain reaction technology-based testing for Chlamydia trachomatis and Neisseria gonorrhea directly from Cytyc ThinPrep Pap Test collection vial samples.
Cytyc/Roche Trials Of PCR Tests With ThinPrep Samples To Start In November
Cytyc and Roche Diagnostics plan to commence patient enrollment in November for a four-site clinical trial of Roche Cobas Amplicor polymerase chain reaction technology-based testing for Chlamydia trachomatis and Neisseria gonorrhea directly from Cytyc ThinPrep Pap Test collection vial samples.
Integra Life Sciences/ArthroCare
510(k) clearance for ArthroCare's Coblation-based spinal surgery system for use in neurosurgery allows Integra to launch the product immediately in the U.S. under an agreement for marketing in North and South America (1"The Gray Sheet" July 31, 2000, p. 18). ArthroCare received a CE mark for the product in February